S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
First-In-Class Nasdaq Pharmaceutical Therapies (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
First-In-Class Nasdaq Pharmaceutical Therapies (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
First-In-Class Nasdaq Pharmaceutical Therapies (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
First-In-Class Nasdaq Pharmaceutical Therapies (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
First-In-Class Nasdaq Pharmaceutical Therapies (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
First-In-Class Nasdaq Pharmaceutical Therapies (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
First-In-Class Nasdaq Pharmaceutical Therapies (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
First-In-Class Nasdaq Pharmaceutical Therapies (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
First-In-Class Nasdaq Pharmaceutical Therapies (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
First-In-Class Nasdaq Pharmaceutical Therapies (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
First-In-Class Nasdaq Pharmaceutical Therapies (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
First-In-Class Nasdaq Pharmaceutical Therapies (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
FRA:EVK

Evonik Industries (EVK) Price Target & Analyst Ratings

€16.98
-0.34 (-1.96%)
(As of 10/2/2023 ET)
Compare
Today's Range
€16.96
€17.46
50-Day Range
€17.20
€18.89
52-Week Range
€26.78
€32.97
Volume
912,661 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
€23.11

Evonik Industries Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

N/A
Based on 0 Analyst Ratings

Consensus Analyst Price Target

€23.11
High Prediction€29.00
Average Prediction€23.11
Low Prediction€15.00
TypeCurrent
10/3/22 to 10/3/23
1 Month Ago
9/3/22 to 9/3/23
3 Months Ago
7/5/22 to 7/5/23
1 Year Ago
10/3/21 to 10/3/22
Consensus RatingN/AN/AN/AN/A
Strong Buy N/A N/A N/A N/A
Buy N/A N/A N/A N/A
Hold N/A N/A N/A N/A
Sell N/A N/A N/A N/A
Consensus Price Target€23.11€23.11€23.72€27.63
Get Evonik Industries Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EVK and its competitors with MarketBeat's FREE daily newsletter.


EVK Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EVK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Evonik Industries Stock vs. The Competition

TypeEvonik IndustriesBasic Materials Companies
Consensus Rating Score
0.00
2.56
Consensus RatingN/AModerate Buy
News Sentiment RatingNeutral News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/4/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Georgina Fraser
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€20.00+3.82%
4/3/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Chetan Udeshi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€28.00+44.63%
3/17/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Chris Counihan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€17.70-5.75%
3/8/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sebastian Bray
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€23.00+11.65%
3/8/2023Warburg Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Oliver Schwarz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€28.60+38.83%
3/7/2023DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Peter Spengler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€21.00-0.28%
3/3/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tim Jones
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€27.00+33.53%
3/2/2023Baader Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Konstantin Wiechert
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€20.00-1.14%
3/2/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Gunther Zechmann
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€29.00+43.35%
3/2/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Geoff Haire
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€19.00-6.08%
2/22/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Alex Stewart
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€29.00+43.28%
12/15/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jean-Baptiste Rolland
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target€15.00-17.29%
(Data available from 10/3/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












EVK Price Target - Frequently Asked Questions

Does Evonik Industries's stock price have much upside?

According to analysts, Evonik Industries's stock has a predicted upside of 16.05% based on their 12-month price targets.


Stock Ratings Reports and Tools

This page (FRA:EVK) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -